Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Monte Rosa Therapeutics's total assets was $691.16M at Jun 30, 2026. For fiscal 2025 it was $448.66M, up 2.3% from the year before. The highest annual figure on record is $448.66M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.66M | +2.3% |
| FY2024 | Dec 31, 2024 | $438.73M | +44.4% |
| FY2023 | Dec 31, 2023 | $303.76M | -11.3% |
| FY2022 | Dec 31, 2022 | $342.39M | -6.5% |
| FY2021 | Dec 31, 2021 | $366.33M | +641.9% |
| FY2020 | Dec 31, 2020 | $49.38M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $691.16M | +92.2% |
| Q1 FY2026 | Mar 31, 2026 | $736.43M | +87.3% |
| Q4 FY2025 | Dec 31, 2025 | $448.66M | +2.3% |
| Q3 FY2025 | Sep 30, 2025 | $459.84M | +45.9% |
| Q2 FY2025 | Jun 30, 2025 | $359.59M | +4.5% |
| Q1 FY2025 | Mar 31, 2025 | $393.20M | +47.4% |
| Q4 FY2024 | Dec 31, 2024 | $438.73M | +44.4% |
| Q3 FY2024 | Sep 30, 2024 | $315.08M | +25.0% |
| Q2 FY2024 | Jun 30, 2024 | $344.11M | +23.5% |
| Q1 FY2024 | Mar 31, 2024 | $266.75M | -13.7% |
| Q4 FY2023 | Dec 31, 2023 | $303.76M | -11.3% |
| Q3 FY2023 | Sep 30, 2023 | $252.10M | -29.5% |
| Q2 FY2023 | Jun 30, 2023 | $278.62M | -23.7% |
| Q1 FY2023 | Mar 31, 2023 | $309.03M | -10.7% |
| Q4 FY2022 | Dec 31, 2022 | $342.39M | -6.5% |
| Q3 FY2022 | Sep 30, 2022 | $357.60M | -6.9% |
| Q2 FY2022 | Jun 30, 2022 | $365.06M | -1.1% |
| Q1 FY2022 | Mar 31, 2022 | $346.01M | +600.7% |
| Q4 FY2021 | Dec 31, 2021 | $366.33M | – |
| Q3 FY2021 | Sep 30, 2021 | $384.05M | – |
| Q2 FY2021 | Jun 30, 2021 | $368.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $49.38M | – |
See a number that looks wrong?